You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
TOKYO, April 27, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it booked an impairment loss for intangible assets and recorded extraordinary losses in the non-consolidated financial results as follows.
・ Details of impairment loss for intangible assets
As a result of a strategic halt of AT132 (resamirigene bilparvovec) for the treatment of X-linked myotubular myopathy and a redeployment of resources to ASP2957, a next-generation investigational gene therapy, Astellas reevaluated the intangible asset and booked an impairment loss for intangible assets of ¥16.4 billion related to AT132 as other expenses.
The above is reflected in the financial results of Astellas for FY2025 which were announced today.
・ Details of extraordinary losses
Astellas recorded JPY 74.8 billion of extraordinary losses in the non-consolidated financial results in the fourth quarter of fiscal year 2025, as a loss on valuation of investment in subsidiaries and affiliates. This is due to the results of a decline in the substantial value of shares of Ogeda B.V., a consolidated subsidiary of Astellas.
The above loss on valuation of investment in subsidiaries and affiliates did not impact consolidated results as it was eliminated in the consolidated financial statements.
About Astellas
Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at.
www.astellas.com.
Cautionary Notes
In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
Contacts for inquiries or additional information:
Astellas Pharma Inc.
Communications and Investor Relations
+81-3-3244-3201
Follow us
